title: Efffect of addition of low-dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients.
abstract: OBJECTIVE
  We designed a multi-center, double-blind, randomized, parallel, with metformin controlled clinical trial to evaluate the efficacy and safety of low dose rosiglitazone combined with sulphonylurea therapy in type 2 diabetic patients who were inadequately controlled with sulphonylurea alone.
  
  
  METHODS
  Patients were treated with 4 mg rosiglitazone once daily plus sulphonylurea (test group) or 0.5 g metformin twice daily plus sulphonylurea (control group) for 12 weeks. The mean levels of HbA(1c), fasting and postprandial plasma glucose were recorded and compared between the two groups.
  
  
  RESULTS
  The mean levels of HbA(1c) decreased by 1.09% and 0.95% in the test group (n = 102) and control group (n = 96) respectively. Fasting and postprandial plasma glucose levels in the test group decreased by 25.0% and 35.6%, and in the control group, decreased by 17.7% and 23.8% as compared with the baseline (both P < 0.01). No liver damage was found.
  
  
  CONCLUSIONS
  Combination treatment of rosiglitazone and sulphonylurea can effectively improve glycemic control in type 2 diabetic patients inadequately controlled with sulphonylurea alone.
authors.affiliation: Department of Endocrinology, Tongren Hospital, Capital University of Medical Sciences, Beijing 100730, China. jinkuiyang@hotmail.com
authors.forename: Jinkui
authors.initials: J
authors.lastname: Yang
authors.forename: Fusong
authors.initials: F
authors.lastname: Di
authors.forename: Ronghua
authors.initials: R
authors.lastname: He
authors.forename: Xuesu
authors.initials: X
authors.lastname: Zhu
authors.forename: Dequan
authors.initials: D
authors.lastname: Wang
authors.forename: Minggong
authors.initials: M
authors.lastname: Yang
authors.forename: Yangang
authors.initials: Y
authors.lastname: Wang
authors.forename: Shenyuan
authors.initials: S
authors.lastname: Yuan
authors.forename: Jiawei
authors.initials: J
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008687:Metformin / Q000008:administration & dosage; D008875:Middle Aged; D000077154:Rosiglitazone; D013453:Sulfonylurea Compounds / Q000008:administration & dosage*; D013844:Thiazoles / Q000008:administration & dosage*; D045162:Thiazolidinediones
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D008687:Metformin